{Reference Type}: Journal Article
{Title}: Facile synthesis of elastin nanogels encapsulated decursin for castrated resistance prostate cancer therapy.
{Author}: Rather GA;Selvakumar P;Srinivas KS;Natarajan K;Kaushik A;Rajan P;Lee SR;Sing WL;Alkhamees M;Lian S;Holley M;Do Jung Y;Lakshmanan VK;
{Journal}: Sci Rep
{Volume}: 14
{Issue}: 1
{Year}: 2024 07 2
{Factor}: 4.996
{DOI}: 10.1038/s41598-024-65999-x
{Abstract}: Nanogels offer hope for precise drug delivery, while addressing drug delivery hurdles is vital for effective prostate cancer (PCa) management. We developed an injectable elastin nanogels (ENG) for efficient drug delivery system to overcome castration-resistant prostate cancer (CRPC) by delivering Decursin, a small molecule inhibitor that blocks Wnt/βcatenin pathways for PCa. The ENG exhibited favourable characteristics such as biocompatibility, flexibility, and low toxicity. In this study, size, shape, surface charge, chemical composition, thermal stability, and other properties of ENG were used to confirm the successful synthesis and incorporation of Decursin (DEC) into elastin nanogels (ENG) for prostate cancer therapy. In vitro studies demonstrated sustained release of DEC from the ENG over 120 h, with a pH-dependent release pattern. DU145 cell line induces moderate cytotoxicity of DEC-ENG indicates that nanomedicine has an impact on cell viability and helps strike a balance between therapeutics efficacy and safety while the EPR effect enables targeted drug delivery to prostate tumor sites compared to free DEC. Morphological analysis further supported the effectiveness of DEC-ENG in inducing cell death. Overall, these findings highlight the promising role of ENG-encapsulated decursin as a targeted drug delivery system for CRPC.